Haemonetics (NYSE: HAE) reported Q2 EPS of $1.12, $0.05 better than the analyst estimate of $1.07. Revenue for the quarter came in at $346 million versus the consensus estimate of $342.58 million.

GUIDANCE:

Haemonetics sees FY2025 EPS of $4.45-$4.75, versus the consensus of $4.59.

For earnings history and earnings-related data on Haemonetics (HAE) click here.